Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
**Background:** Atrial fibrillation (AF) is a chronic sustained heart rhythm disorder associated with an increased risk of stroke. Apixaban, a new oral anticoagulant, was approved by the European Medicines Agency for prevention of stroke in patients with AF. The efficacy of apixaban has been investi...
Saved in:
Main Authors: | Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb, Sid Ahmed Kherraf |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2017-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9797 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
by: Carlos Rubio-Terrés, et al.
Published: (2016-02-01) -
The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
by: Nadir Hammoumraoui, et al.
Published: (2013-10-01) -
Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
by: Li Wang, et al.
Published: (2013-11-01) -
Detecting Atrial Fibrillation Using Smartwatches
by: Agnieszka Kulczycka-Rowicka, et al.
Published: (2025-02-01) -
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
by: Raffaele De Caterina, et al.
Published: (2019-03-01)